Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation

R. Porta, B. Massutí, L. Paz-Ares, N. Reguart, J.M. Sánchez, C. Mayo, P. Lianes, C. Queralt, V. Guillem, P. Salinas, S. Catot, D. Isla, A. Pradas, A. Gúrpide, J. de Castro, E. Polo, T. Puig, M. Tarón, R. Colomer, R. Rosell
European Respiratory Journal 2010; DOI: 10.1183/09031936.00195609
R. Porta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B. Massutí
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L. Paz-Ares
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N. Reguart
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J.M. Sánchez
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Mayo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Lianes
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Queralt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
V. Guillem
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Salinas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Catot
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Isla
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Pradas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Gúrpide
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. de Castro
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E. Polo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. Puig
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Tarón
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Colomer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rcolomer@seom.org
R. Rosell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Median survival of patients with brain metastases from non-small-cell lung (NSCLC) cancer is poor, and more effective treatments are urgently needed. We have evaluated the efficacy of erlotinib in this setting and its association with activating mutations in the EGFR gene.

We retrospectively identified patients with NSCLC and brain metastases treated with erlotinib. EGFR mutations in exons 19 and 21 were analysed by direct sequencing. Efficacy and tolerability were compared according to EGFR mutational status.

Sixty-nine NSCLC patients with brain metastases were identified, 17 of whom harboured EGFR mutations. Objective response rate in patients with EGFR mutations was 82.4%; no responses were observed in unselected patients (p<0.001). Time to progression within the brain for patients harbouring EGFR mutations was 11.7 months (95%CI, 7.9–15.5), compared to 5.8 months (95%CI, 5.2–6.4) for control patients, whose EGFR mutational status had not been assessed (p<0.05). Overall survival was 12.9 (95%CI, 6.2–19.7) and 3.1 months (95%CI, 2.5–3.9; p<0.001), respectively. The toxicity of erlotinib was as expected and no differences between both cohorts observed.

Erlotinib is active in brain metastases from NSCLC; this clinical benefit is related to the presence of activating mutations in exons 19 or 21 of the EGFR gene.

  • ErbB
  • metastases
  • mutation screening
  • non-small cel lung cancer
  • targeted therapy
  • ERS
Next
Back to top
Vol 61 Issue 3 Table of Contents
European Respiratory Journal: 61 (3)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation
R. Porta, B. Massutí, L. Paz-Ares, N. Reguart, J.M. Sánchez, C. Mayo, P. Lianes, C. Queralt, V. Guillem, P. Salinas, S. Catot, D. Isla, A. Pradas, A. Gúrpide, J. de Castro, E. Polo, T. Puig, M. Tarón, R. Colomer, R. Rosell
European Respiratory Journal Jan 2010, erj01956-2009; DOI: 10.1183/09031936.00195609

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation
R. Porta, B. Massutí, L. Paz-Ares, N. Reguart, J.M. Sánchez, C. Mayo, P. Lianes, C. Queralt, V. Guillem, P. Salinas, S. Catot, D. Isla, A. Pradas, A. Gúrpide, J. de Castro, E. Polo, T. Puig, M. Tarón, R. Colomer, R. Rosell
European Respiratory Journal Jan 2010, erj01956-2009; DOI: 10.1183/09031936.00195609
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Genetics
  • Lung biology and experimental studies
  • Lung cancer
  • Mechanisms of lung disease
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Lung volumes and survival in chronic lung allograft dysfunction
  • Aspergillus fumigatus in COPD
  • Calcineurin inhibitors in bronchiolitis obliterans syndrome
Show more Original article

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society